Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVA237 crossover study on exercise endurance in moderate to severe COPD
2010-018597-20Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of glycopyrronium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoint: Exercise endurance time during SMETT after 3 weeks. Started Jun 2010; status: completed.
02
Drugs
glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2010-018597-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018597-20.